Amgen has announced a significant $1 billion investment to build a second drug substance manufacturing facility in North Carolina. This expansion is part of the company’s ongoing effort to enhance its U.S. biomanufacturing capabilities and meet increasing global demand for its therapies.
Strengthening Global Biomanufacturing Network
The new facility will complement Amgen’s existing $550 million investment in Holly Springs, bringing the total planned investment in the area to over $1.5 billion. This expansion aims to incorporate cutting-edge technologies and sustainable practices, while creating 370 new jobs in the region. The new facility, alongside the original one, will play a key role in Amgen’s efforts to provide reliable and efficient delivery of critical medicines worldwide.
Amgen’s chairman and CEO, Robert Bradway, expressed that the North Carolina location will be vital in strengthening the company’s global manufacturing network and meeting the growing demand for its life-saving therapies. “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact,” said Bradway.
Boosting North Carolina’s Biotech Reputation
North Carolina Governor Roy Cooper welcomed the investment, emphasizing that it further elevates the state’s status as a global biotechnology leader. He praised the state’s skilled, diverse workforce, tailored to meet the specific needs of the biotech industry, and noted that Amgen’s investment will contribute to the sector’s continued growth.
This announcement follows Amgen’s recent updates on positive trial results for its investigational therapies, including the promising results for its antibody peptide conjugate, MariTide, and the successful phase 3 trial of Uplizna for treating generalized myasthenia gravis.
